MAPI Research Trust provides reliable, comprehensive and up-to-date information services to research scientists, pharmaceutical companies, and governmental health agencies involved in the fields of Patient-Reported Outcomes (PRO) and Pharmaco-Epidemiology worldwide.
Home
history
As a non-profit organization, MAPI Research Trust is in a truly unique position among companies that serve the information needs of research scientists, pharmaceutical companies, and governmental health agencies around the world.


MAPI Research Trust provides reliable, comprehensive and up-to-date information services to those in the field of Patient-Reported Outcomes (PRO) and Pharmaco-Epidemiology around the globe.

Through two unique databases, developed and constantly updated by MAPI Research Trust research professionals, we not only exchange the latest health outcomes information but also create vital links among those at every level of PRO and Pharmaco-Epidemiological studies. We also maintain the world’s largest library devoted exclusively to PROs and make its wealth of information available to those who need it most.

Whether it’s information about a PRO questionnaire or an in-depth literature review, the MAPI Research Trust team is ready to make a difference.

We welcome you to our website and invite you to learn more about everything the MAPI Research Trust can offer you.

 

To access our catalog, please click here.

New questionnaires distributed by MAPI Research Trust

ACCEPT (Chronic Treatment Acceptance Questionnaire)
MAPI SAS / Registrat MAPI (France)

ADRQL (Alzheimer Disease Related Quality of Life)
Black Betty S, Kasper Judith D and Rabins Peter V. - Johns Hopkins Medical INstitutions (USA)

ESS (Epworth Sleepiness Scale) 
Murray W. Johns (Australia)

FIRST (Fibromyalgia Rapid Screening Tool)
Serge Perrot & Didier Bouhassira (France)

PDSS-2 (Parkinson's Disease Sleep Scale)
Ray Chaudhuri (UK) & Claudia Trenkwalder (Germany)

Skindex questionnaire 
Mary-Margaret Chren (USA)

TRIM-D and TRIM-D Device (Treatment Related Impact Measure for Diabetes)
Novo Nordisk (Denmark)